Cannabis for Medical Use: Analysis of Recent Clinical Trials in View of Current Legislation

Abstract

Cannabis has long been regarded as a recreational substance in the Western world. The recent marketing authorization of some medicinal products of industrial origin and the introduction onto the market of inflorescences for medical use mean that medical doctors can now prescribe Cannabis-based medicines in those countries which allow it. Nevertheless, there is still considerable controversy on this topic in the scientific community. In particular, this controversy concerns: the plant species to be used; the pathologies that can be treated and consequently the efficacy and safety of use; the routes of administration; the methods of preparation; the type and dosage of cannabinoids to be used; and, the active molecules of interest. As such, although medical Cannabis has been historically used, the results of currently completed and internationally published studies are inconclusive and often discordant. In light of these considerations, the aim of this work is to analyse the current legislation in countries that allow the use of medical Cannabis, in relation to the impact that this legislation has had on clinical trials. First of all, a literature search has been performed (PubMed and SciFinder) on clinical trials which involved the administration of Cannabis for medical use over the last 3 years. Of the numerous studies extrapolated from the literature, only about 43 reported data on clinical trials on medical Cannabis, with these mainly being performed in Australia, Brazil, Canada, Denmark, Germany, Israel, Netherlands, Switzerland, the United Kingdom and the United States of America. Once the reference countries were identified, an evaluation of the legislation in relation to Cannabis for medical use in each was carried out via the consultation of the pertinent scientific literature, but also of official government documentation and that of local regulatory authorities. This analysis provided us with an overview of the different legislation in these countries and, consequently, allowed us to analyse, with greater awareness, the results of the clinical trials published in the last 3 years in order to obtain general interest indications in the prosecution of scientific research in this area.

Exploring the Potential of Cannabinoid Nanodelivery Systems for CNS Disorders

“…Due to the process of legalization, the use of marijuana in the last year of young adults aged 19–30 years increased significantly, compared with five and ten years earlier, reaching historical highs [ 13 , 14 , 15 ]. Concomitantly with the increased use of cannabinoid, rapid assays for on-site cannabinoids detection in oral fluids have been developed [ 16 , 17 ].…”

Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment

“…As the target groups for medicinal cannabis include critically ill patients, they should not be exposed to risks associated with poor-quality products. The quality of cannabis products is therefore essential to consider [ 47 , 58 , 59 ]. Generally speaking, medicinal cannabis is of considerably higher and more constant quality than recreational cannabis purchased from a coffee shop.…”

Medical cannabis: Exploring therapeutic perspectives and regulatory context

“…It has since been followed by more than twenty of the 27 countries, including Switzerland, Belgium, Italy and Germany. The most common initial approach has been to use some form of special access regime, generally creating a system of medical approval and supervision, limiting medical use to a restricted set of conditions and often restricting the cannabis-based preparations that patients can use [31,32].…”

“…Inflorescences can also be taken as a decoction or inhaled through vaporisers. Cannabis is indicated for treating the symptoms of pathologies including, but not limited to, multiple sclerosis, HIV, cancer, pain and Tourette's syndrome, refractory glaucoma, epilepsy and epileptic syndromes (even in children) [32,33].…”